An Open-label, Multicenter Study Providing Continuation of Nilotinib in Adult Patients With Imatinib-(Glivec®/Gleevec®) - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase
Inclusion Criteria:
- Having participated in Novartis study CAMN107A2109, and
- Written signed and dated informed consent prior to any study procedures being
performed.
Exclusion Criteria:
- Impaired cardiac function,
- Use of therapeutic coumarin derivatives (i.e., warfarin, acenocoumarol,
phenprocoumon) up to the day before study drug administration; Other concurrent
severe and/or uncontrolled medical conditions,
- Patients who are currently receiving treatment with any of the medications that have
the potential to prolong the QT interval,
- patients who have undergone a major surgery and have not recovered from side effects
of such therapy within 15 days,
- Patients who are pregnant or breast feeding or adults of reproductive potential not
employing an effective method of birth control, OR
- Patients unwilling or unable to comply with the protocol.
Other protocol -defined inclusion/exclusion criteria may apply